Table 3.
Odds of developing pouchitis after ileal pouch-anal anastomosis for ulcerative colitis
| Odds Ratio | 95% Confidence Interval | |
|---|---|---|
| Indication for Colectomy | ||
| Medically-refractory ulcerative colitis | Reference | Reference |
| Dysplasia or cancer | 0.80 | 0.49 – 1.31 |
| Emergent colectomy | 0.75 | 0.35 – 1.62 |
| Female sex | 1.46 | 1.04 – 2.07 |
| Age | ||
| 18–34 years | Reference | Reference |
| 35–44 years | 1.61 | 0.99 – 2.62 |
| 45–54 years | 1.41 | 0.90 – 2.23 |
| 55–64 years | 1.10 | 0.66 – 1.83 |
| Primary sclerosing cholangitis | 3.94 | 1.05 – 14.8 |
| Smoker/tobacco abose | 1.24 | 0.64 – 2.39 |
| Deyo Modification of Charlson Comorbidity Index Score | ||
| 0 | Reference | Reference |
| 1 | 1.05 | 0.68 – 1.62 |
| 2 | 0.97 | 0.53 – 1.78 |
| 3 or more | 1.19 | 0.66 – 2.17 |
| Residence Region | ||
| Northeast | Reference | Reference |
| Midwest | 1.06 | 0.67 – 1.68 |
| South | 0.94 | 0.56 – 1.56 |
| West | 1.11 | 0.55 – 2.22 |
| Plan type | ||
| Preferred Provider Organization | Reference | Reference |
| Health Maintenance Organization | 0.29 | 0.07 −1.15 |
| Consumer Directed Health Care | 1.27 | 0.78 – 2.05 |
| Other | 0.83 | 0.49 – 1.42 |
| Year of index date | ||
| 2007 | Reference | Reference |
| 2008 | 0.84 | 1.32 – 2.18 |
| 2009 | 0.86 | 0.33 – 2.56 |
| 2010 | 0.83 | 0.32 – 2.17 |
| 2011 | 0.88 | 0.33 – 2.36 |
| 2012 | 0.77 | 0.28 – 2.12 |
| 2013 | 0.72 | 0.24 – 2.12 |
| 2014 | 0.39 | 0.12 – 1.30 |
| Use of mesalamine prior to colectomy | 1.72 | 1.19 – 2.48 |
| Use of immunomodulator prior to colectomy | 1.04 | 0.68 – 1.59 |
| Use of anti-TNF prior to colectomy | 1.63 | 1.09 – 2.45 |
| Use of corticosteroids prior to colectomy | 1.09 | 0.75 – 1.59 |
Anti-tumor necrosis factor alpha (anti-TNF); ileal pouch-anal anastomosis (IPAA)